Comments
Motilal Oswal Financial
Eris Lifesciences (Buy)
Target: ₹870
CMP: ₹733.05
We initiate coverage on Eris Lifesciences (ERIS) with a Buy rating and a target price of ₹870. In just 14 years (founded in CY07), Eris has built a pure-play branded formulation business, with a revenue of ₹1,300 crore (12 month ending Sep’21). Notably, its PAT has nearly doubled to ₹350 crore during FY16–21.
Eris Lifesciences ranks among the Top 25 Indian companies in revenue terms. It has presence across the value chain in developing, manufacturing, and marketing of branded pharma products in select chronic therapies (the fastest growing company in chronic category), such as anti diabetes, cardiac care, and vitamins/minerals/nutrients.
We expect a 17 per cent earnings CAGR for Eris over FY21–24 versus marginal earnings growth during FY18–21, driven by: higher scope of penetration of technically superior drugs in AD therapy (adding Insulin-analogs to the AD portfolio); its efforts to improve the coverage of super-specialists/high-end consulting physicians across therapies; better operating leverage on improved MR productivity; and higher in-house manufacturing.
We ascribe a three-year industry average P/E multiple of 22x on 12M forward earnings to arrive at our target price.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.